Abstracts Archive - Page 107 of 2607 - ACR Meeting Abstracts

Abstract Number: 1191 • ACR Convergence 2025
Effect of ER Stress Inhibition With 4-Phenylbutyric Acid on Disease Phenotype in a Mouse Model of Myositis
Alfredo Guzman, Elizabeth Bagley, Rita Spathis, Madison King, Kanneboyina Nagaraju and Melissa Morales, Binghamton University, Johnson City, NY
Background/Purpose: Dysregulation of the ER stress and interferon (IFN) pathways play a major role in the pathophysiology of autoimmune myositis. Upregulation of ER stress markers…
Abstract Number: 1179 • ACR Convergence 2025
Efficacy and Safety of Ruxolitinib in Adult Patients With Refractory Connective Tissue Disease-Associated Macrophage Activation Syndrome
Jingjing Li¹, Ran Wang¹, Jie Chen¹, Antao xu¹, Yakai Fu¹, Yanwei Lin¹, Xiaodong Wang¹, Shuang Ye², Fang Du¹ and Qiong Fu³, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ²Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai, Shanghai, China
Background/Purpose: Macrophage activation syndrome (MAS) is a rare and life-threatening complication of connective tissue diseases (CTDs), with approximately 30% of cases being refractory to standard…
Abstract Number: 1193 • ACR Convergence 2025
Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis
Angela Chang¹, Navid Saleh¹, Alec Yu¹, Darya S. Jalaledin², Sabrina Hoa³, Robert Levy⁴, Jennifer Wilson⁵, Charles Poirier⁶, John Yee¹, James Choi¹, Océane Landon-Cardinal⁷, Hyein Kim⁸ and Kun Huang⁹, ¹University of British Columbia, Vancouver, BC, Canada, ²Université de Montréal, Saint-Lambert, QC, Canada, ³University of Montreal, Brossard, QC, Canada, ⁴University of British Columbia, Deerfield, IL, ⁵UBC, Vancouver, BC, Canada, ⁶University of Montreal, Montreal, QC, Canada, ⁷Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸The University of British Columbia, Vancouver, BC, Canada, ⁹University of British Columbia, Vancouver, Surrey, BC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of idiopathic inflammatory myositis (IIM) and systemic sclerosis (SSc), ranging from subclinical ILD to rapidly progressive…
Abstract Number: 1113 • ACR Convergence 2025
Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort
Qi Wang¹, Zhiting Tang² and Lei Deng³, ¹Metrohealth System/Case Western Reserve University, Cleveland, OH, ²Unity Hospital, Rochester, NY, ³Fred Hutchinson Cancer Center, Seattle, WA
Background/Purpose: Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare but life-threatening immune-related adverse event (irAE), with a mortality rate of 30–50%. Most available evidence comes…
Abstract Number: 1078 • ACR Convergence 2025
Trends in Hospitalization rate with Lupus in the State of Florida: A retrospective data review from Florida Health Charts from 1992-2023
Muhammad Sohaib Asghar¹, Mohammed Akram², Veerkaran Banga¹, rajkaran Banga¹, Woo Joo Lee¹, Afsana Ansari Shaik³, Syed Muhammad Muneeb Akhtar⁴ and Thomas Shimshak¹, ¹AdventHealth Sebring, Sebring, FL, ²HCA Aventura, Aventura, FL, ³Mayo Clinic, Rochester, MN, ⁴Dow University of Health Sciences, Karachi, Pakistan
Background/Purpose: Lupus is a systemic autoimmune disease that occurs when the body's immune system attacks its own tissues and organs. This study was conducted to…
Abstract Number: 1092 • ACR Convergence 2025
Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Binod Kc¹, Aakritee Sharma Subedi¹, Salome Walsh¹, Areeba Memon¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by enhancing the immune system's ability to fight cancer. However, their use is associated with immune-related…
Abstract Number: 1184 • ACR Convergence 2025
Does Blocking IL-17 Treat Recalcitrant Uveitis? Explorative Study on the Use of Ixekizumab to Manage Patients with Uveitis.
Sergio Schwartzman¹, Stephen Anesi², Yasmin Massoudi², Monica Schwartzman³ and Peter Chang², ¹Weill Cornell Medical Center, New York Presbyterian Hospital, and Hospital for Special Surgery, New York, NY, ²MERSI, Waltham, ³Hospital for Special Surgery/New York Presbyterian Hospital-Weill Cornell Medical Center, New Rochelle, NY
Background/Purpose: Non-infectious uveitis can exist as a primary autoimmune disease or can be a manifestation of an underlying systemic illness. Despite the availability of new…
Abstract Number: 1188 • ACR Convergence 2025
Aortic Wall Shear Stress May Be a Protective Factor Against Development of Spinal Osteoproliferation
Sevtap Arslan Sarikaya¹, Büşra Fırlatan Yazgan², Ozan Sakir³, Adalet Elcin Yildiz⁴, Ustun Aydingoz⁵ and Umut Kalyoncu², ¹Department of Radiology, Hacettepe University School of Medicine, Ankara, Turkey, ankara, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ³Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, ⁴Department of Radiology, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, ⁵[email protected], Ankara, Turkey
Background/Purpose: Diffuse idiopathic skeletal hyperostosis (DISH) is often characterized by new bone formation along the right anterolateral spinal column, particularly in the thoracic region (1,…
Abstract Number: 1202 • ACR Convergence 2025
High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort
Ka Ki Yam¹, Lucas Tsz Ho Luk¹, Weng Nga Lao², Chiu Wai Shirley Chan³, Dennis Tin Ho Chan⁴, Billy Tin Lok Lai⁵, Roy Tsz Chung Ho⁶, Vivian Hoi Shan Tang⁷, Ho So⁸ and Iris Tang⁹, ¹Department of Medicine & Geriatrics, Hong Kong, Hong Kong, ²Department of Medicine & Geriatrics, Kwong Wah Hospital, Hong Kong, Hong Kong, ³Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ⁴Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁵Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, ⁶Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁷Department of Medicine, North District Hospital, Hong Kong, Hong Kong, ⁸Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁹Department of Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Interstitial lung disease (ILD) is a common and severe complication of idiopathic inflammatory myopathies (IIM), adversely impacting clinical outcomes. While the ACR/CHEST guideline recommends…
Abstract Number: 1185 • ACR Convergence 2025
Pulmonary Arterial Hypertension in Adults with Still’s Disease: Another Pulmonary Manifestation Associated with HLA-DRB1*15
Stéphane Mitrovic¹, Athénaïs Boucly², Maryvonnick Carmagnat³, Laurent Savale², Xavier Jaïs², Jean-luc Taupin³, Estibaliz Lazaro⁴, Emilie Berthoux⁵, nicolas schleinitz⁶, Maria-Rosa Ghigna⁷, kedra joanna¹, Xavier Mariette⁸, Céline Roussin⁹, Pierre Antoine Juge¹⁰, Marc Humbert², Olivier Sitbon², David Montani² and Bruno Fautrel¹¹, ¹Pitié-Salpêtrière Hospital, Rheumatology Department, APHP, Sorbonne University,, Paris, France, ²Kremlin Bicêtre Hospital, Pulmonology Department, Paris Saclay University, APHP, Le Kremlin Bicêtre, France, ³Saint Louis Hospital, Immunology laboratory, APHP, Paris, France, ⁴Internal Medicine Department, CHU Bordeaux, Bordeaux, France, ⁵Saint Joseph Sain Luc Hospital, Internal Medicine Department, Lyon, Lyon, France, ⁶Aix Marseille university, AP-HM, Marseille, France, ⁷Marie Lannelongue Hospital, Anatomopathology department, Le Plessis-Robinson, France, ⁸Université Paris-Saclay, Le Kremlin Bicetre, France, ⁹Centre Hospitalier Ouest Réunion, Saint Paul, France, ¹⁰Hopital Bichat, APHP, Paris, France, ¹¹Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Inflammatory lung disease (ILD) in Still’s disease (SD) has recently been described. Pulmonary arterial hypertension (PAH), a rare subtype of pulmonary hypertension (PH), is…
Abstract Number: 1038 • ACR Convergence 2025
Real-World Immunosuppressant Treatment Patterns in Lupus Nephritis: A Retrospective Claims Database Analysis in the United States
Anisha Patel¹, Alexandra Miller¹, Lisa Lindsay¹, Danny Sheinson¹, Zhiyu Xia¹, William Pendergraft¹ and Maria Dall'Era², ¹Genentech, Inc., South San Francisco, CA, ²Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: LN is a severe manifestation of SLE requiring intensive management. We aimed to characterize real-world treatment patterns in newly diagnosed patients with LN within…
Abstract Number: 1208 • ACR Convergence 2025
Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression
Jia Shi¹, Yang Wu², Aviya Levy³, Ting Wang⁴, Abhinav Janappareddi⁵, Payton Hermanson¹, Jorge A. Gonzalez-Chapa⁵, Qian Wang⁶, Susan Shenoi⁷ and Christian Lood⁵, ¹University of Washington, Seattle, WA, ²¹. Chinese Academy of Medical Sciences & Peking Union Medical College; ². Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China; ³. University of Washington, Division of Rheumatology, Seattle, WA, USA, Beijing, China (People's Republic), ³Rady Children's Hospital, San Diego, CA, ⁴Division of Rheumatology, Seattle Children's Hospital and Research Center, Seattle, ⁵University of Washington, Division of Rheumatology, Seattle, ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷Seattle Children's Hospital and Research Center, Mercer Island, WA
Background/Purpose: Juvenile dermatomyositis (JDM) is an inflammatory vasculopathy characterized by muscle weakness and systemic inflammation. This study aimed to investigate the clinical utility of neutrophil…
Abstract Number: 1216 • ACR Convergence 2025
Measurement Properties of a Shorter Health Assessment Questionnaire (HAQ-II) in Patients with Inflammatory Myopathies
Sung-Ki Lee¹, Kristin Wipfler², Ethan Ritz³, Burcu Aydemir⁴, Kaleb Michaud⁵ and Didem Saygin⁶, ¹Rush Medical College, Chicago, IL, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Rush Research Informatics Core, Rush University Medical Center, Chicago, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Rush University Medical Center, Chicago, IL
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune disorders characterized by chronic skeletal muscle inflammation leading to muscle weakness and limitations in physical…
Abstract Number: 1189 • ACR Convergence 2025
Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
Valerie Devauchelle¹, Swati Ghanshani², CAROLE SIPS³, Rainer Hillenbrand³, Carol Lau⁴, Wolfgang Hueber⁵, Claire Bonal³ and Stephen Oliver⁶, ¹UBO, Brest, France, ²Novartis Healthcare Private Limited, Hyderabad, India, Hyderabad, India, ³Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab, a glycoengineered IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via dual mechanism: depletion of B…
Abstract Number: 1230 • ACR Convergence 2025
Chronic pain phenotypes in older adults: Identifying patterns of musculoskeletal pain and associated burden
Gillian Fennell¹, Sarah Tilley², Sayali Dhamne³, Robert Edwards⁴, Mary Gheller³, Angelo Demalia³, Margaret Clancy³, Michael LaValley⁵, Emelia J Benjamin³ and Tuhina Neogi⁶, ¹Boston University Medical, Boston, MA, ²Boston University School of Medicine, Somerville, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁴Brigham and Women's Hospital & Harvard Medical School, Boston, MA, ⁵Boston University School of Public Health, Arlington, MA, ⁶Boston University School of Medicine, Boston, MA
Background/Purpose: Over a third of older Americans experience chronic pain, typically occupying multiple musculoskeletal body sites. While number of pain sites (NPS) is often touted…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].